Intellia therapeutics, inc. (NTLA)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
Collaboration revenue

12,916

10,936

10,616

11,118

10,433

7,880

7,408

7,677

7,469

6,668

7,317

5,917

6,215

5,627

4,869

4,206

1,777

1,693

1,688

1,377

1,286

Operating expenses:
Research and development

34,650

31,731

27,513

25,460

23,709

19,918

23,237

23,467

22,493

21,170

17,481

15,565

13,431

11,331

7,861

7,423

5,225

4,375

3,458

1,966

1,371

General and administrative

11,314

8,976

8,431

13,118

10,533

8,708

8,270

7,805

7,406

10,213

5,711

6,369

5,732

5,118

4,705

3,729

3,246

2,809

1,531

2,833

1,110

Total operating expenses

45,964

40,707

35,944

38,578

34,242

28,626

31,507

31,272

29,899

31,383

23,192

21,934

19,163

16,449

12,566

11,152

8,471

7,184

4,989

4,799

2,481

Operating loss

-33,048

-29,771

-25,328

-27,460

-23,809

-20,746

-24,099

-23,595

-22,430

-24,715

-15,875

-16,017

-12,948

-10,822

-7,697

-6,946

-6,694

-5,491

-3,301

-3,422

-1,195

Interest income

1,242

1,495

1,694

1,777

1,869

1,680

1,397

1,376

1,074

752

519

424

317

259

215

46

5

-

-

-

-

Loss before income taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-5,491

-3,301

-3,422

-1,195

Income tax benefit

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-246

-282

-382

-102

Net loss

-31,806

-28,276

-23,634

-25,683

-21,940

-19,066

-22,702

-22,219

-21,356

-23,963

-15,356

-15,593

-12,631

-10,563

-7,482

-6,900

-6,689

-5,245

-3,019

-3,040

-1,093

Net loss per share, basic and diluted

-0.63

-0.57

-0.49

-0.56

-0.49

-0.43

-0.53

-0.52

-0.51

-0.61

-0.44

-0.45

-0.36

-0.31

-0.22

-0.36

-9.89

-9.57

-10.27

-2.37

-0.85

Weighted average shares outstanding, basic and diluted

50,491

49,350

48,554

45,814

45,234

44,215

43,161

42,836

42,043

39,155

35,189

34,916

34,723

34,507

34,316

19,121

676

548

294

1,284

1,284

Other comprehensive loss:
Unrealized gain on marketable securities

112

-75

81

196

87

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comprehensive loss

-31,694

-28,351

-23,553

-25,487

-21,853

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-